Company Profile

Aeolus Pharmaceuticals is developing a new class of broad-spectrum, catalytic-antioxidant compounds that protect healthy tissue from the damaging effects of radiation. Its first compound, AEOL 10150, is being developed, with funding by the US Department of Health and Human Services, as a medical countermeasure against chemical and radiological weapons, where its initial target indications are as a protective agent against the effects of acute radiation syndrome and delayed effects of acute radiation exposure. Aeolus' strategy is to leverage the substantial investment in toxicology, manufacturing, and preclinical and clinical studies made by US Government agencies in AEOL 10150, including the contract with BARDA valued, with options, at up to $118.4 million, to efficiently develop the compound for use in oncology.

Aeolus Pharmaceuticals Investor Presentation

Investor Presentation

View our latest Corporate Presentation

View Presentation

Stock Snapshot

AOLS Symbol
OTCQB Market
Market Cap
Price
Change
Volume
Go to Detailed Stock Information ›

Upcoming Events

View IR Calendar ›

Recent News

Go to Press Releases ›